# OnCo record dart-s1609 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/dart-s1609/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "dart-s1609", "NCT02834013" ;
  schema:name "DART (SWOG S1609): nivolumab plus ipilimumab in rare tumours"@en ;
  schema:alternateName "DART"@en, "S1609"@en, "Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors"@en ;
  schema:description "DART gives the same two immunotherapy drugs to people with dozens of different rare cancers, each cancer in its own small group, so that rare diseases nobody would build a trial for get an answer. It found real responses in high-grade neuroendocrine cancers and in angiosarcoma."@en ;
  schema:url <https://onco.cc/trials/dart-s1609/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02834013>, <https://doi.org/10.1158/1078-0432.CCR-19-3356> ;
  onco:status "active" ;
  onco:phase "2" ;
  schema:startDate "2017-01-30" ;
  onco:cancers <https://onco.cc/terms/rare-cancers/>, <https://onco.cc/cancers/neuroendocrine/>, <https://onco.cc/cancers/extrapulmonary-nec/>, <https://onco.cc/cancers/vascular-tumours/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:companies <https://onco.cc/companies/swog/> ;
  onco:institutions <https://onco.cc/institutions/nci/> ;
  onco:terms <https://onco.cc/terms/master-protocol/>, <https://onco.cc/terms/basket-umbrella-platform/>, <https://onco.cc/terms/tmb/> ;
  onco:people <https://onco.cc/people/razelle-kurzrock/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/> .